🟠 Moderate Evidence
Two Phase 1 clinical trials have demonstrated the safety and tolerability of rimteravimab (XVR011), a novel heavy chain-only antibody designed to treat mild-to-moderate COVID-19. The studies, published in PLOS Medicine, evaluated the experimental therapy in both healthy volunteers and hospitalized COVID-19 patients.
Key takeaways
- Rimteravimab showed acceptable safety across all tested doses (250mg, 500mg, 1000mg) in Phase 1 trials
- The antibody targets the receptor binding domain of SARS-CoV-2 spike protein using innovative VHH technology
- Development was discontinued due to loss of potency against Omicron BA.2 variant
Study at a Glance
| Source | PLOS Medicine |
| Study type | Randomized controlled trial |
| Sample size | Healthy volunteers and COVID-19 patients |
| Population | Healthy adults and hospitalized mild-moderate COVID-19 patients |
| Country | Multi-center European study |
Rimteravimab dose escalation in Phase 1 trials
Three ascending doses tested across healthy volunteers and COVID-19 patients
Source: Jansen et al., PLOS Medicine, 2024 | Georgian Medical Journal News
Novel antibody design targets SARS-CoV-2
Rimteravimab represents an innovative approach to COVID-19 treatment, utilizing Variable Heavy domain of Heavy chains (VHH) technology. According to the research team led by Ellen Jansen, the antibody consists of two identical VHHs that target the receptor binding domain of the SARS-CoV-2 spike protein, combined with a human IgG1 fragment.
The World Health Organization has emphasized the continued need for effective therapeutic options as SARS-CoV-2 variants emerge. This research contributes to understanding how heavy chain-only antibodies might be developed for clinical use, though few such constructs have reached this stage of development.
Safety demonstrated across dose ranges
The Phase 1a study (EXEVIR0102) was conducted as a randomized, double-blinded, placebo-controlled trial in healthy volunteers, while Phase 1b (EXEVIR0101) involved hospitalized COVID-19 patients in an open-label design. Both studies evaluated safety and tolerability as their primary objective, according to the published findings.
For more insights on clinical updates in infectious disease therapeutics, researchers are continuing to explore novel antibody platforms. The studies also examined pharmacokinetics, efficacy measures including respiratory parameters, and immunogenicity profiles across the tested populations.
Phase 1 trials demonstrated acceptable safety and tolerability of rimteravimab across all tested dose levels in both healthy volunteers and hospitalized COVID-19 patients
— Ellen Jansen, lead researcher, PLOS Medicine, 2024
Development halted due to variant resistance
Despite promising safety results, the development program faced a significant setback when rimteravimab lost potency against the SARS-CoV-2 Omicron BA.2 variant. This led to the discontinuation of Part 2 of the EXEVIR0101 study, which was initially planned as a phase 1b/2 trial, according to the research team.
The challenge highlights broader issues in global health responses to rapidly evolving pathogens. As variants continue to emerge, therapeutic developers must balance the time required for clinical development with the shifting landscape of viral mutations that can render treatments ineffective.
What this means
Frequently asked questions
What makes VHH antibodies different from conventional antibodies?
VHH antibodies are derived from heavy chain-only antibodies found in camelids and can target unique epitopes that conventional antibodies cannot reach. They are smaller and potentially more stable than traditional antibodies.
Why was rimteravimab development discontinued?
The antibody lost its potency against the SARS-CoV-2 Omicron BA.2 variant, which became dominant during the study period. This made continued development unlikely to provide clinical benefit.
What can be learned from these Phase 1 results?
The safety and tolerability data provide important insights for developing future VHH-based therapeutics, establishing that this antibody platform can be safely administered to humans across a range of doses.
The research represents an important contribution to the scientific understanding of VHH-based therapeutics, even as the specific compound will not advance to later-stage trials. Future antibody development efforts may benefit from the pharmacokinetic and safety insights generated by these carefully conducted Phase 1 studies, particularly as researchers continue exploring heavy chain-only antibodies for various therapeutic applications.
Was this article helpful?
Related Coverage
